Public Profile

Nipro Pharma Corporation

Nipro Pharma Corporation, a leading player in the pharmaceutical industry, is headquartered in Japan and operates extensively across Asia, Europe, and the Americas. Founded in 1954, the company has established itself as a key provider of high-quality medical products, particularly in the fields of dialysis, infusion therapy, and injectable pharmaceuticals. Nipro's commitment to innovation is evident in its diverse range of core products, which include advanced medical devices and pharmaceutical formulations designed to enhance patient care. The company is recognised for its rigorous quality standards and has achieved significant milestones, including numerous certifications and awards that underscore its market position. With a focus on research and development, Nipro Pharma continues to drive advancements in healthcare, making it a trusted name in the global pharmaceutical landscape.

DitchCarbon Score

How does Nipro Pharma Corporation's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

13

Industry Average

Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

14

Industry Benchmark

Nipro Pharma Corporation's score of 13 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.

0%

Nipro Pharma Corporation's reported carbon emissions

Nipro Pharma Corporation, headquartered in Japan, currently does not have publicly available carbon emissions data or specific reduction targets. As such, there are no reported figures for their Scope 1, 2, or 3 emissions. The absence of emissions data suggests that the company may still be in the early stages of formalising its climate commitments or reporting practices. In the context of the pharmaceutical industry, many companies are increasingly focusing on sustainability and carbon reduction initiatives. Nipro Pharma Corporation may be expected to align with industry standards and best practices in the future, potentially adopting science-based targets or other climate pledges to mitigate their environmental impact. However, without specific data or commitments, it is difficult to assess their current position on climate action.

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Nipro Pharma Corporation's primary industry is Chemicals nec, which is medium in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. Nipro Pharma Corporation is headquartered in JP, which has a rank of low, indicating low grid carbon intensity.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Nipro Pharma Corporation is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero

Similar Organizations

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers